LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 16

Search options

  1. Article ; Online: Mutation analysis of disease causing genes in patients with early onset or familial forms of Alzheimer's disease and frontotemporal dementia.

    Pagnon de la Vega, María / Näslund, Carl / Brundin, RoseMarie / Lannfelt, Lars / Löwenmark, Malin / Kilander, Lena / Ingelsson, Martin / Giedraitis, Vilmantas

    BMC genomics

    2022  Volume 23, Issue 1, Page(s) 99

    Abstract: Background: Most dementia disorders have a clear genetic background and a number of disease genes have been identified. Mutations in the tau gene (MAPT) lead to frontotemporal dementia (FTD), whereas mutations in the genes for the amyloid-β precursor ... ...

    Abstract Background: Most dementia disorders have a clear genetic background and a number of disease genes have been identified. Mutations in the tau gene (MAPT) lead to frontotemporal dementia (FTD), whereas mutations in the genes for the amyloid-β precursor protein (APP) and the presenilins (PSEN1, PSEN2) cause early-onset, dominantly inherited forms of Alzheimer's disease (AD). Even if mutations causing Mendelian forms of these diseases are uncommon, elucidation of the pathogenic effects of such mutations have proven important for understanding the pathogenic processes. Here, we performed a screen to identify novel pathogenic mutations in known disease genes among patients undergoing dementia investigation.
    Results: Using targeted exome sequencing we have screened all coding exons in eleven known dementia genes (PSEN1, PSEN2, APP, MAPT, APOE, GRN, TARDBP, CHMP2B, TREM2, VCP and FUS) in 102 patients with AD, FTD, other dementia diagnoses or mild cognitive impairment. We found three AD patients with two previously identified pathogenic mutations in PSEN1 (Pro264Leu and Met146Val). In this screen, we also identified the recently reported APP mutation in two siblings with AD. This mutation, named the Uppsala mutation, consists of a six amino acid intra-amyloid β deletion. In addition, we found several potentially pathogenic mutations in PSEN2, FUS, MAPT, GRN and APOE. Finally, APOE ε4 was prevalent in this patient group with an allele frequency of 54%.
    Conclusions: Among the 102 screened patients, we found two disease causing mutations in PSEN1 and one in APP, as well as several potentially pathogenic mutations in other genes related to neurodegenerative disorders. Apart from giving important information to the clinical investigation, the identification of disease mutations can contribute to an increased understanding of disease mechanisms.
    MeSH term(s) Alzheimer Disease/genetics ; Amyloid beta-Peptides ; Frontotemporal Dementia/genetics ; Humans ; Membrane Glycoproteins ; Mutation ; Presenilin-1/genetics ; Presenilin-2/genetics ; Receptors, Immunologic
    Chemical Substances Amyloid beta-Peptides ; Membrane Glycoproteins ; Presenilin-1 ; Presenilin-2 ; Receptors, Immunologic ; TREM2 protein, human
    Language English
    Publishing date 2022-02-04
    Publishing country England
    Document type Journal Article
    ZDB-ID 2041499-7
    ISSN 1471-2164 ; 1471-2164
    ISSN (online) 1471-2164
    ISSN 1471-2164
    DOI 10.1186/s12864-022-08343-9
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Different Inflammatory Signatures in Alzheimer's Disease and Frontotemporal Dementia Cerebrospinal Fluid.

    Boström, Gustaf / Freyhult, Eva / Virhammar, Johan / Alcolea, Daniel / Tumani, Hayrettin / Otto, Markus / Brundin, Rose-Marie / Kilander, Lena / Löwenmark, Malin / Giedraitis, Vilmantas / Lleó, Alberto / von Arnim, Christine A F / Kultima, Kim / Ingelsson, Martin

    Journal of Alzheimer's disease : JAD

    2021  Volume 81, Issue 2, Page(s) 629–640

    Abstract: Background: Neuroinflammatory processes are common in neurodegenerative diseases such as Alzheimer's disease (AD) and frontotemporal dementia (FTD), but current knowledge is limited as to whether cerebrospinal fluid (CSF) levels of neuroinflammatory ... ...

    Abstract Background: Neuroinflammatory processes are common in neurodegenerative diseases such as Alzheimer's disease (AD) and frontotemporal dementia (FTD), but current knowledge is limited as to whether cerebrospinal fluid (CSF) levels of neuroinflammatory proteins are altered in these diseases.
    Objective: To identify and characterize neuroinflammatory signatures in CSF from patients with AD, mild cognitive impairment (MCI), and FTD.
    Methods: We used proximity extension assay and ANOVA to measure and compare levels of 92 inflammatory proteins in CSF from 42 patients with AD, 29 with MCI due to AD (MCI/AD), 22 with stable MCI, 42 with FTD, and 49 control subjects, correcting for age, gender, collection unit, and multiple testing.
    Results: Levels of matrix metalloproteinase-10 (MMP-10) were increased in AD, MCI/AD, and FTD compared with controls (AD: fold change [FC] = 1.32, 95% confidence interval [CI] 1.14-1.53, q = 0.018; MCI/AD: FC = 1.53, 95% CI 1.20-1.94, q = 0.045; and FTD: FC = 1.42, 95% CI 1.10-1.83, q = 0.020). MMP-10 and eleven additional proteins were increased in MCI/AD, compared with MCI (q < 0.05). In FTD, 36 proteins were decreased, while none was decreased in AD or MCI/AD, compared with controls (q < 0.05).
    Conclusion: In this cross-sectional multi-center study, we found distinct patterns of CSF inflammatory marker levels in FTD and in both early and established AD, suggesting differing neuroinflammatory processes in the two disorders.
    MeSH term(s) Aged ; Alzheimer Disease/cerebrospinal fluid ; Alzheimer Disease/diagnosis ; Amyloid beta-Peptides/cerebrospinal fluid ; Biomarkers/cerebrospinal fluid ; Cognitive Dysfunction/cerebrospinal fluid ; Cognitive Dysfunction/diagnosis ; Cross-Sectional Studies ; Female ; Frontotemporal Dementia/cerebrospinal fluid ; Frontotemporal Dementia/diagnosis ; Humans ; Inflammation/cerebrospinal fluid ; Inflammation/diagnosis ; Male ; Middle Aged ; Peptide Fragments/cerebrospinal fluid ; tau Proteins/cerebrospinal fluid
    Chemical Substances Amyloid beta-Peptides ; Biomarkers ; Peptide Fragments ; tau Proteins
    Language English
    Publishing date 2021-04-02
    Publishing country Netherlands
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 1440127-7
    ISSN 1875-8908 ; 1387-2877
    ISSN (online) 1875-8908
    ISSN 1387-2877
    DOI 10.3233/JAD-201565
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Improved Differential Diagnosis of Alzheimer's Disease by Integrating ELISA and Mass Spectrometry-Based Cerebrospinal Fluid Biomarkers.

    Khoonsari, Payam Emami / Shevchenko, Ganna / Herman, Stephanie / Remnestål, Julia / Giedraitis, Vilmantas / Brundin, RoseMarie / Degerman Gunnarsson, Malin / Kilander, Lena / Zetterberg, Henrik / Nilsson, Peter / Lannfelt, Lars / Ingelsson, Martin / Kultima, Kim

    Journal of Alzheimer's disease : JAD

    2019  Volume 67, Issue 2, Page(s) 639–651

    Abstract: Background: Alzheimer's disease (AD) is diagnosed based on a clinical evaluation as well as analyses of classical biomarkers: Aβ42, total tau (t-tau), and phosphorylated tau (p-tau) in cerebrospinal fluid (CSF). Although the sensitivities and ... ...

    Abstract Background: Alzheimer's disease (AD) is diagnosed based on a clinical evaluation as well as analyses of classical biomarkers: Aβ42, total tau (t-tau), and phosphorylated tau (p-tau) in cerebrospinal fluid (CSF). Although the sensitivities and specificities of the classical biomarkers are fairly good for detection of AD, there is still a need to develop novel biochemical markers for early detection of AD.
    Objective: We explored if integration of novel proteins with classical biomarkers in CSF can better discriminate AD from non-AD subjects.
    Methods: We applied ELISA, mass spectrometry, and multivariate modeling to investigate classical biomarkers and the CSF proteome in subjects (n = 206) with 76 AD patients, 74 mild cognitive impairment (MCI) patients, 11 frontotemporal dementia (FTD) patients, and 45 non-dementia controls. The MCI patients were followed for 4-9 years and 21 of these converted to AD, whereas 53 remained stable.
    Results: By combining classical CSF biomarkers with twelve novel markers, the area of the ROC curves (AUROCS) of distinguishing AD and MCI/AD converters from non-AD were 93% and 96%, respectively. The FTDs and non-dementia controls were identified versus all other groups with AUROCS of 96% and 87%, respectively.
    Conclusions: Integration of new and classical CSF biomarkers in a model-based approach can improve the identification of AD, FTD, and non-dementia control subjects.
    MeSH term(s) Adult ; Aged ; Aged, 80 and over ; Alzheimer Disease/cerebrospinal fluid ; Alzheimer Disease/diagnosis ; Amyloid beta-Peptides/cerebrospinal fluid ; Biomarkers/cerebrospinal fluid ; Cognitive Dysfunction/cerebrospinal fluid ; Cognitive Dysfunction/diagnosis ; Diagnosis, Differential ; Disease Progression ; Enzyme-Linked Immunosorbent Assay ; Female ; Follow-Up Studies ; Frontotemporal Dementia/cerebrospinal fluid ; Frontotemporal Dementia/diagnosis ; Humans ; Male ; Mass Spectrometry ; Middle Aged ; Peptide Fragments/cerebrospinal fluid ; Proteome ; Sensitivity and Specificity ; tau Proteins/cerebrospinal fluid
    Chemical Substances Amyloid beta-Peptides ; Biomarkers ; MAPT protein, human ; Peptide Fragments ; Proteome ; amyloid beta-protein (40-42) ; tau Proteins
    Language English
    Publishing date 2019-01-07
    Publishing country Netherlands
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 1440127-7
    ISSN 1875-8908 ; 1387-2877
    ISSN (online) 1875-8908
    ISSN 1387-2877
    DOI 10.3233/JAD-180855
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: The

    Pagnon de la Vega, María / Giedraitis, Vilmantas / Michno, Wojciech / Kilander, Lena / Güner, Gökhan / Zielinski, Mara / Löwenmark, Malin / Brundin, RoseMarie / Danfors, Torsten / Söderberg, Linda / Alafuzoff, Irina / Nilsson, Lars N G / Erlandsson, Anna / Willbold, Dieter / Müller, Stephan A / Schröder, Gunnar F / Hanrieder, Jörg / Lichtenthaler, Stefan F / Lannfelt, Lars /
    Sehlin, Dag / Ingelsson, Martin

    Science translational medicine

    2021  Volume 13, Issue 606

    Abstract: Point mutations in the amyloid precursor protein gene ( ...

    Abstract Point mutations in the amyloid precursor protein gene (
    MeSH term(s) Alzheimer Disease/genetics ; Amyloid Precursor Protein Secretases/metabolism ; Amyloid beta-Peptides/metabolism ; Amyloid beta-Protein Precursor/genetics ; Amyloid beta-Protein Precursor/metabolism ; Brain/metabolism ; Humans
    Chemical Substances Amyloid beta-Peptides ; Amyloid beta-Protein Precursor ; Amyloid Precursor Protein Secretases (EC 3.4.-)
    Language English
    Publishing date 2021-08-08
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2518854-9
    ISSN 1946-6242 ; 1946-6234
    ISSN (online) 1946-6242
    ISSN 1946-6234
    DOI 10.1126/scitranslmed.abc6184
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Increased Number of Plasma B Cells Producing Autoantibodies Against Aβ42 Protofibrils in Alzheimer's Disease.

    Söllvander, Sofia / Ekholm-Pettersson, Frida / Brundin, Rose-Marie / Westman, Gabriel / Kilander, Lena / Paulie, Staffan / Lannfelt, Lars / Sehlin, Dag

    Journal of Alzheimer's disease : JAD

    2015  Volume 48, Issue 1, Page(s) 63–72

    Abstract: The Alzheimer's disease (AD)-related peptide amyloid-β (Aβ) has a propensity to aggregate into various assemblies including toxic soluble Aβ protofibrils. Several studies have reported the existence of anti-Aβ antibodies in humans. However, it is still ... ...

    Abstract The Alzheimer's disease (AD)-related peptide amyloid-β (Aβ) has a propensity to aggregate into various assemblies including toxic soluble Aβ protofibrils. Several studies have reported the existence of anti-Aβ antibodies in humans. However, it is still debated whether levels of anti-Aβ antibodies are altered in AD patients compared to healthy individuals. Formation of immune complexes with plasma Aβ makes it difficult to reliably measure the concentration of circulating anti-Aβ antibodies with certain immunoassays, potentially leading to an underestimation. Here we have investigated anti-Aβ antibody production on a cellular level by measuring the amount of anti-Aβ antibody producing cells instead of the plasma level of anti-Aβ antibodies. To our knowledge, this is the first time the anti-Aβ antibody response in plasma has been compared in AD patients and age-matched healthy individuals using the enzyme-linked immunospot (ELISpot) technique. Both AD patients and healthy individuals had low levels of B cells producing antibodies binding Aβ40 monomers, whereas the number of cells producing antibodies toward Aβ42 protofibrils was higher overall and significantly higher in AD compared to healthy controls. This study shows, by an alternative and reliable method, that there is a specific immune response to the toxic Aβ protofibrils, which is significantly increased in AD patients.
    MeSH term(s) Aged ; Aged, 80 and over ; Alzheimer Disease/blood ; Alzheimer Disease/immunology ; Amyloid beta-Peptides/immunology ; Amyloid beta-Peptides/metabolism ; Autoantibodies/metabolism ; B-Lymphocytes/metabolism ; Biotinylation ; Case-Control Studies ; Enzyme-Linked Immunosorbent Assay ; Female ; Flow Cytometry ; Humans ; Male ; Mental Status Schedule ; Peptide Fragments/immunology ; Peptide Fragments/metabolism
    Chemical Substances Amyloid beta-Peptides ; Autoantibodies ; Peptide Fragments ; amyloid beta-protein (1-40) ; amyloid beta-protein (1-42)
    Language English
    Publishing date 2015
    Publishing country Netherlands
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 1440127-7
    ISSN 1875-8908 ; 1387-2877
    ISSN (online) 1875-8908
    ISSN 1387-2877
    DOI 10.3233/JAD-150236
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Interference from heterophilic antibodies in amyloid-β oligomer ELISAs.

    Sehlin, Dag / Söllvander, Sofia / Paulie, Staffan / Brundin, RoseMarie / Ingelsson, Martin / Lannfelt, Lars / Pettersson, Frida Ekholm / Englund, Hillevi

    Journal of Alzheimer's disease : JAD

    2011  Volume 21, Issue 4, Page(s) 1295–1301

    Abstract: Amyloid-β (Aβ) oligomers of different sizes and forms have recently been the focus formany Alzheimer's disease (AD) researchers. Various immunoassays have been used to detect low concentrations of these elusive Aβ species in different forms of human ... ...

    Abstract Amyloid-β (Aβ) oligomers of different sizes and forms have recently been the focus formany Alzheimer's disease (AD) researchers. Various immunoassays have been used to detect low concentrations of these elusive Aβ species in different forms of human samples using little or no sample dilutions. However, the possibility that positive results may be caused by interference from heterophilic antibodies (HA) is often overlooked. HA, which recognize immunoglobulins from other species, are present in human plasma and cerebrospinal fluid (CSF) and may cause interference in sandwich immunoassays like enzyme-linked immunosorbent assays (ELISAs) by cross-binding the capture and detection antibodies of the assay. They thus may generate a false positive signal. Here we show that when assessing the Aβ oligomer content in plasma samples from 44 individuals with a sandwich ELISA, none of the 21 positive signals remained when the assay was repeated in the presence of factors blocking HA. Similarly, in CSF samples from 104 individuals, the signals from the 22 positive samples were strongly reduced when analyzed after anti-HA treatment. Taken together, HA interference is a problem that needs to be addressed when measuring low levels of an antigen in human plasma and CSF samples.
    MeSH term(s) Aged ; Aged, 80 and over ; Alzheimer Disease/blood ; Alzheimer Disease/cerebrospinal fluid ; Alzheimer Disease/immunology ; Amyloid beta-Peptides/blood ; Amyloid beta-Peptides/cerebrospinal fluid ; Amyloid beta-Protein Precursor/blood ; Amyloid beta-Protein Precursor/cerebrospinal fluid ; Amyloid beta-Protein Precursor/immunology ; Animals ; Antibodies, Heterophile/blood ; Antibodies, Heterophile/cerebrospinal fluid ; Binding Sites, Antibody/immunology ; Biomarkers/blood ; Enzyme-Linked Immunosorbent Assay/standards ; False Positive Reactions ; Humans ; Mice ; Mice, Transgenic ; Middle Aged ; Protein Multimerization/immunology
    Chemical Substances APP protein, human ; Amyloid beta-Peptides ; Amyloid beta-Protein Precursor ; Antibodies, Heterophile ; Biomarkers
    Language English
    Publishing date 2011-04-18
    Publishing country Netherlands
    Document type Comparative Study ; Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 1440127-7
    ISSN 1875-8908 ; 1387-2877
    ISSN (online) 1875-8908
    ISSN 1387-2877
    DOI 10.3233/jad-2010-100609
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: The Arctic AβPP mutation leads to Alzheimer's disease pathology with highly variable topographic deposition of differentially truncated Aβ.

    Kalimo, Hannu / Lalowski, Maciej / Bogdanovic, Nenad / Philipson, Ola / Bird, Thomas D / Nochlin, David / Schellenberg, Gerard D / Brundin, Rosemarie / Olofsson, Tommie / Soliymani, Rabah / Baumann, Marc / Wirths, Oliver / Bayer, Thomas A / Nilsson, Lars N G / Basun, Hans / Lannfelt, Lars / Ingelsson, Martin

    Acta neuropathologica communications

    2013  Volume 1, Page(s) 60

    Abstract: Background: The Arctic mutation (p.E693G/p.E22G)fs within the β-amyloid (Aβ) region of the β-amyloid precursor protein gene causes an autosomal dominant disease with clinical picture of typical Alzheimer's disease. Here we report the special character ... ...

    Abstract Background: The Arctic mutation (p.E693G/p.E22G)fs within the β-amyloid (Aβ) region of the β-amyloid precursor protein gene causes an autosomal dominant disease with clinical picture of typical Alzheimer's disease. Here we report the special character of Arctic AD neuropathology in four deceased patients.
    Results: Aβ deposition in the brains was wide-spread (Thal phase 5) and profuse. Virtually all parenchymal deposits were composed of non-fibrillar, Congo red negative Aβ aggregates. Congo red only stained angiopathic vessels. Mass spectrometric analyses showed that Aβ deposits contained variably truncated and modified wild type and mutated Aβ species. In three of four Arctic AD brains, most cerebral cortical plaques appeared targetoid with centres containing C-terminally (beyond aa 40) and variably N-terminally truncated Aβ surrounded by coronas immunopositive for Aβx-42. In the fourth patient plaque centres contained almost no Aβ making the plaques ring-shaped. The architectural pattern of plaques also varied between different anatomic regions. Tau pathology corresponded to Braak stage VI, and appeared mainly as delicate neuropil threads (NT) enriched within Aβ plaques. Dystrophic neurites were scarce, while neurofibrillary tangles were relatively common. Neuronal perikarya within the Aβ plaques appeared relatively intact.
    Conclusions: In Arctic AD brain differentially truncated abundant Aβ is deposited in plaques of variable numbers and shapes in different regions of the brain (including exceptional targetoid plaques in neocortex). The extracellular non-fibrillar Aβ does not seem to cause overt damage to adjacent neurons or to induce formation of neurofibrillary tangles, supporting the view that intracellular Aβ oligomers are more neurotoxic than extracellular Aβ deposits. However, the enrichment of NTs within plaques suggests some degree of intra-plaque axonal damage including accumulation of hp-tau, which may impair axoplasmic transport, and thereby contribute to synaptic loss. Finally, similarly as the cotton wool plaques in AD resulting from exon 9 deletion in the presenilin-1 gene, the Arctic plaques induced only modest glial and inflammatory tissue reaction.
    MeSH term(s) Aged ; Alzheimer Disease/genetics ; Alzheimer Disease/metabolism ; Alzheimer Disease/pathology ; Amyloid beta-Peptides/metabolism ; Amyloid beta-Protein Precursor/genetics ; Brain/metabolism ; Brain/pathology ; European Continental Ancestry Group/genetics ; Family ; Humans ; Middle Aged ; Mutation ; Pedigree ; Sweden
    Chemical Substances APP protein, human ; Amyloid beta-Peptides ; Amyloid beta-Protein Precursor
    Language English
    Publishing date 2013-09-10
    Publishing country England
    Document type Case Reports ; Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
    ZDB-ID 2715589-4
    ISSN 2051-5960 ; 2051-5960
    ISSN (online) 2051-5960
    ISSN 2051-5960
    DOI 10.1186/2051-5960-1-60
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Frontotemporal dementia-amyotrophic lateral sclerosis complex is simulated by neurodegeneration with brain iron accumulation.

    Santillo, Alexander Frizell / Skoglund, Lena / Lindau, Maria / Eeg-Olofsson, Karin Edebol / Tovi, Metin / Engler, Henry / Brundin, Rose-Marie / Ingvast, Sofie / Lannfelt, Lars / Glaser, Anna / Kilander, Lena

    Alzheimer disease and associated disorders

    2009  Volume 23, Issue 3, Page(s) 298–300

    Abstract: We describe a case of late onset neurodegeneration with brain iron accumulation (NBIA) presenting as frontotemporal dementia (FTD) with amyotrophic lateral sclerosis (ALS). A male patient presented at age 66 with change of personality: disinhibition, ... ...

    Abstract We describe a case of late onset neurodegeneration with brain iron accumulation (NBIA) presenting as frontotemporal dementia (FTD) with amyotrophic lateral sclerosis (ALS). A male patient presented at age 66 with change of personality: disinhibition, emotional blunting, and socially inappropriate behavior, coupled with dysarthria, dystonia, and corticospinal tract involvement. Magnetic resonance imaging showed general cortical atrophy, iron deposits in the globus pallidus, and the "eye of the tiger" sign. Neuropsychologic performance was globally reduced, especially executive functions. Fluorodeoxyglucose positron emission tomography showed hypometabolism predominantly in frontal and temporal areas. Repeated neurophysiologic examinations showed signs of chronic denervation. The patient was diagnosed with NBIA but fulfilled consensus criteria for FTD and had a clinical picture of ALS, without neurophysiologic confirmation. Our finding introduces NBIA as a possible cause of FTD and as a differential diagnosis of the FTD-ALS complex.
    MeSH term(s) Aged ; Amyotrophic Lateral Sclerosis/physiopathology ; Brain/metabolism ; Brain/pathology ; Diagnosis, Differential ; Electromyography ; Frontotemporal Dementia/physiopathology ; Humans ; Iron/metabolism ; Magnetic Resonance Imaging ; Male ; Neuropsychological Tests ; Pantothenate Kinase-Associated Neurodegeneration/diagnosis ; Pantothenate Kinase-Associated Neurodegeneration/pathology ; Pantothenate Kinase-Associated Neurodegeneration/physiopathology ; Pedigree ; Positron-Emission Tomography
    Chemical Substances Iron (E1UOL152H7)
    Language English
    Publishing date 2009-07
    Publishing country United States
    Document type Case Reports ; Journal Article
    ZDB-ID 1002700-2
    ISSN 1546-4156 ; 0893-0341
    ISSN (online) 1546-4156
    ISSN 0893-0341
    DOI 10.1097/WAD.0b013e3181a2b76b
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: No evidence of PGRN or MAPT gene dosage alterations in a collection of patients with frontotemporal lobar degeneration.

    Skoglund, Lena / Ingvast, Sofie / Matsui, Toshifumi / Freeman, Stefanie H / Frosch, Matthew P / Brundin, Rosemarie / Giedraitis, Vilmantas / Growdon, John H / Hyman, Bradley T / Lannfelt, Lars / Ingelsson, Martin / Glaser, Anna

    Dementia and geriatric cognitive disorders

    2009  Volume 28, Issue 5, Page(s) 471–475

    Abstract: Background/aims: Alterations in gene dosage have recently been associated with neurodegenerative disorders, such as Alzheimer's disease and Parkinson's disease, and deletions of the progranulin (PGRN) locus were recently described in patients with ... ...

    Abstract Background/aims: Alterations in gene dosage have recently been associated with neurodegenerative disorders, such as Alzheimer's disease and Parkinson's disease, and deletions of the progranulin (PGRN) locus were recently described in patients with frontotemporal lobar degeneration (FTLD). FTLD is a genetically complex neurodegenerative disorder with mutations in the PGRN and the microtubule-associated protein tau (MAPT) genes being the most common known causes of familial FTLD. In this study, we investigated 39 patients with FTLD, previously found negative for mutations in PGRN and MAPT, for copy number alterations of these 2 genes.
    Methods: Gene dosage analysis of PGRN and MAPT was performed using multiplex ligation-dependent probe amplification.
    Results: We did not identify any PGRN or MAPT gene dosage variations in the 39 FTLD patients investigated.
    Conclusion: We therefore conclude that alterations in gene copy number of PGRN and MAPT are not a cause of disease in this collection of FTLD patients.
    MeSH term(s) Frontotemporal Lobar Degeneration/genetics ; Gene Deletion ; Gene Dosage ; Gene Duplication ; Humans ; Intercellular Signaling Peptides and Proteins/genetics ; Nucleic Acid Amplification Techniques ; Progranulins ; tau Proteins/genetics
    Chemical Substances GRN protein, human ; Intercellular Signaling Peptides and Proteins ; MAPT protein, human ; Progranulins ; tau Proteins
    Language English
    Publishing date 2009-11-23
    Publishing country Switzerland
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 1026007-9
    ISSN 1421-9824 ; 1013-7424
    ISSN (online) 1421-9824
    ISSN 1013-7424
    DOI 10.1159/000260046
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: CALHM1 P86L polymorphism does not alter amyloid-beta or tau in cerebrospinal fluid.

    Giedraitis, Vilmantas / Glaser, Anna / Sarajärvi, Timo / Brundin, RoseMarie / Gunnarsson, Malin Degerman / Schjeide, Brit-Maren / Tanzi, Rudolph E / Helisalmi, Seppo / Pirttilä, Tuula / Kilander, Lena / Lannfelt, Lars / Soininen, Hilkka / Bertram, Lars / Ingelsson, Martin / Hiltunen, Mikko

    Neuroscience letters

    2009  Volume 469, Issue 2, Page(s) 265–267

    Abstract: Recently, the P86L alteration in CALHM1 (calcium homeostasis modulator-1) was reported to be associated with Alzheimer's disease (AD). Moreover, the risk allele increased amyloid-beta (A beta) levels in conditioned media from cultured cells. Therefore, ... ...

    Abstract Recently, the P86L alteration in CALHM1 (calcium homeostasis modulator-1) was reported to be associated with Alzheimer's disease (AD). Moreover, the risk allele increased amyloid-beta (A beta) levels in conditioned media from cultured cells. Therefore, we hypothesized that CALHM1 P86L may modulate A beta or tau levels in cerebrospinal fluid (CSF). Nearly 200 individuals with AD or other cognitive disorders were included for CSF analysis and CALHM1 genotyping. No significant differences in CSF levels of A beta 42, tau or phospho-tau were found across the various CALHM1 genotypes. In conclusion, we found no evidence that CALHM1 P86L is associated with altered CSF levels of the investigated AD biomarkers.
    MeSH term(s) Aged ; Alzheimer Disease/cerebrospinal fluid ; Alzheimer Disease/genetics ; Alzheimer Disease/metabolism ; Amyloid beta-Peptides/cerebrospinal fluid ; Amyloid beta-Peptides/metabolism ; Biomarkers/cerebrospinal fluid ; Biomarkers/metabolism ; Calcium Channels/genetics ; Calcium Channels/metabolism ; Cognition Disorders/cerebrospinal fluid ; Cognition Disorders/genetics ; Cognition Disorders/metabolism ; Cohort Studies ; European Continental Ancestry Group/genetics ; Female ; Finland ; Genotype ; Humans ; Male ; Membrane Glycoproteins/genetics ; Membrane Glycoproteins/metabolism ; Peptide Fragments/cerebrospinal fluid ; Peptide Fragments/metabolism ; Phosphorylation ; Polymorphism, Genetic ; Sequence Analysis, DNA ; Sweden ; tau Proteins/cerebrospinal fluid ; tau Proteins/metabolism
    Chemical Substances Amyloid beta-Peptides ; Biomarkers ; CALHM1 protein, human ; Calcium Channels ; MAPT protein, human ; Membrane Glycoproteins ; Peptide Fragments ; amyloid beta-protein (1-42) ; tau Proteins
    Language English
    Publishing date 2009-12-23
    Publishing country Ireland
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 194929-9
    ISSN 1872-7972 ; 0304-3940
    ISSN (online) 1872-7972
    ISSN 0304-3940
    DOI 10.1016/j.neulet.2009.12.011
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top